Clinical Trial Update: To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ABN401 for safety, pharmacokinetics, pharmacodynamics, and antitumor activity in advanced solid tumors and non-small cell lung cancer w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABN401

Snippet

Sponsor: Abion Inc | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED